Evidence map›Paper›PMID 27847254›Full record

ReviewBone2017

Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho.

Shunsuke Yamada, Cecilia M Giachelli

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bone, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 5 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 5 syntheses or guidelines pooled it, 314 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shunsuke YamadaDepartment of Bioengineering, University of Washington, Seattle, WA 98195, USA.
Cecilia M GiachelliDepartment of Bioengineering, University of Washington, Seattle, WA 98195, USA. Electronic address: ceci@washington.edu.
University of Washington · US

Funding

Vascular Calcification MechanismR01HL062329 · NHLBI · UNIVERSITY OF WASHINGTON · PI GIACHELLI, CECILIA M · 1999 to 2017
$5.3M
Calcification and Vascular Cell DifferentiationR01HL081785 · NHLBI · UNIVERSITY OF WASHINGTON · PI GIACHELLI, CECILIA M · 2005 to 2017
$3.7M
Role of Osteoclastogenesis in Calcific Aortic Valve DiseaseR01HL114611 · NHLBI · UNIVERSITY OF WASHINGTON · PI GIACHELLI, CECILIA M · 2012 to 2016
$1.9M
NHLBI NIH HHS R01 HL062329NHLBI NIH HHS R01 HL081785NHLBI NIH HHS R01 HL114611
6 · The paper itself

Abstract

Vascular calcification (VC) is highly prevalent in aging, diabetes mellitus, and chronic kidney disease (CKD). VC is a strong predictor of cardiovascular morbidity and mortality in the CKD population. Complex pathological mechanisms are involved in the development of VC, including osteochondrogenic differentiation and apoptosis of vascular smooth muscle cells, instability and release of extracellular vesicles loaded calcium and phosphate, and elastin degradation. Elevated serum phosphate is a late manifestation of CKD, and has been shown to accelerate mineral deposition in both the vessel wall and heart valves. α-Klotho and fibroblast growth factor 23 (FGF23) are emerging factors in CKD-mineral and bone disorder (CKD-MBD) and are thought to be involved in the pathogenesis of uremic VC. There are discordant reports regarding the biomedical effects of FGF23 on VC. In contrast, mounting evidence supports a well-supported protective role for α-Klotho on VC. Further studies are warranted to elucidate potential roles of FGF23 and α-Klotho in VC and to determine where and how they are synthesized in normal and disease conditions. A thorough systemic evaluation of the biomedical interplay of phosphate, FGF23, and α-Klotho may potentially lead to new therapeutic options for patients with CKD-MBD.

Indexed as

Chronic Kidney Disease-Mineral and Bone DisorderFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseKlotho ProteinsPhosphatesVascular CalcificationFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseKlotho ProteinsPhosphatesChronic kidney diseaseFibroblast growth factor 23Vascular calcificationα-Klotho

Identifiers

PMID27847254
PMCPMC5429216
OpenAlexW2550881001

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.